| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blepharoptosis | 14 | 2024 | 64 | 5.460 |
Why?
|
| Ophthalmology | 19 | 2025 | 198 | 4.990 |
Why?
|
| Blepharoplasty | 13 | 2024 | 20 | 4.820 |
Why?
|
| Blepharospasm | 11 | 2022 | 44 | 4.610 |
Why?
|
| Eyelids | 18 | 2024 | 104 | 4.550 |
Why?
|
| Ophthalmologic Surgical Procedures | 20 | 2024 | 82 | 4.150 |
Why?
|
| Oculomotor Muscles | 14 | 2024 | 68 | 3.870 |
Why?
|
| Nasolacrimal Duct | 8 | 2024 | 20 | 3.190 |
Why?
|
| Dacryocystorhinostomy | 9 | 2024 | 19 | 2.860 |
Why?
|
| Orbital Diseases | 9 | 2021 | 78 | 2.800 |
Why?
|
| Academies and Institutes | 14 | 2025 | 87 | 2.580 |
Why?
|
| Orbital Neoplasms | 8 | 2024 | 59 | 2.510 |
Why?
|
| Botulinum Toxins | 6 | 2020 | 122 | 2.510 |
Why?
|
| Lacrimal Duct Obstruction | 8 | 2024 | 17 | 2.420 |
Why?
|
| Orbital Implants | 8 | 2021 | 13 | 2.340 |
Why?
|
| Optic Nerve Diseases | 5 | 2023 | 89 | 2.250 |
Why?
|
| Eyelid Diseases | 8 | 2023 | 59 | 2.020 |
Why?
|
| Graves Ophthalmopathy | 3 | 2021 | 14 | 1.920 |
Why?
|
| Orbital Fractures | 6 | 2022 | 34 | 1.910 |
Why?
|
| Conjunctiva | 6 | 2024 | 194 | 1.860 |
Why?
|
| Technology Assessment, Biomedical | 7 | 2021 | 35 | 1.860 |
Why?
|
| Lacrimal Apparatus Diseases | 6 | 2024 | 45 | 1.800 |
Why?
|
| Ambulatory Surgical Procedures | 3 | 2024 | 61 | 1.790 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 3 | 2024 | 64 | 1.570 |
Why?
|
| Orbit | 10 | 2024 | 88 | 1.530 |
Why?
|
| Canaliculitis | 2 | 2023 | 3 | 1.480 |
Why?
|
| Eye Enucleation | 7 | 2021 | 50 | 1.380 |
Why?
|
| Humans | 135 | 2025 | 134156 | 1.370 |
Why?
|
| Dermoid Cyst | 3 | 2023 | 34 | 1.290 |
Why?
|
| Retinoblastoma | 3 | 2019 | 117 | 1.280 |
Why?
|
| Retinal Neoplasms | 3 | 2019 | 103 | 1.270 |
Why?
|
| Hemifacial Spasm | 3 | 2018 | 15 | 1.270 |
Why?
|
| Amyloidosis | 2 | 2021 | 73 | 1.180 |
Why?
|
| Neuromuscular Agents | 5 | 2018 | 67 | 1.150 |
Why?
|
| Botulinum Toxins, Type A | 5 | 2022 | 166 | 1.060 |
Why?
|
| Conjunctival Neoplasms | 2 | 2020 | 18 | 1.040 |
Why?
|
| Cosmetic Techniques | 3 | 2025 | 11 | 1.030 |
Why?
|
| Corneal Diseases | 3 | 2020 | 96 | 0.990 |
Why?
|
| Eyelid Neoplasms | 3 | 2020 | 37 | 0.990 |
Why?
|
| Eye Neoplasms | 3 | 2017 | 53 | 0.980 |
Why?
|
| Cysts | 2 | 2023 | 104 | 0.970 |
Why?
|
| Dacryocystitis | 3 | 2015 | 21 | 0.950 |
Why?
|
| Anophthalmos | 2 | 2021 | 24 | 0.930 |
Why?
|
| Blinking | 3 | 2022 | 26 | 0.890 |
Why?
|
| Surgery, Plastic | 2 | 2023 | 105 | 0.890 |
Why?
|
| Fasciitis | 1 | 2024 | 20 | 0.880 |
Why?
|
| Polypropylenes | 2 | 2014 | 16 | 0.860 |
Why?
|
| Temporal Arteries | 2 | 2019 | 40 | 0.860 |
Why?
|
| Foreign-Body Reaction | 2 | 2014 | 16 | 0.850 |
Why?
|
| Nerve Transfer | 2 | 2020 | 8 | 0.850 |
Why?
|
| Sclera | 2 | 2014 | 50 | 0.840 |
Why?
|
| Cavernous Sinus | 2 | 2019 | 25 | 0.840 |
Why?
|
| Fires | 1 | 2023 | 12 | 0.830 |
Why?
|
| Sutures | 2 | 2014 | 67 | 0.820 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2023 | 2198 | 0.820 |
Why?
|
| Eye Injuries | 2 | 2022 | 48 | 0.810 |
Why?
|
| Williams Syndrome | 1 | 2023 | 42 | 0.800 |
Why?
|
| Dry Eye Syndromes | 4 | 2022 | 280 | 0.800 |
Why?
|
| Tears | 4 | 2020 | 175 | 0.790 |
Why?
|
| Female | 55 | 2024 | 71928 | 0.790 |
Why?
|
| Burns | 1 | 2023 | 100 | 0.780 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2023 | 169 | 0.760 |
Why?
|
| Lacrimal Apparatus | 9 | 2024 | 120 | 0.760 |
Why?
|
| Male | 54 | 2024 | 66127 | 0.740 |
Why?
|
| Oculomotor Nerve Diseases | 2 | 2019 | 18 | 0.730 |
Why?
|
| Materia Medica | 1 | 2021 | 2 | 0.730 |
Why?
|
| Optic Disk | 3 | 2020 | 50 | 0.730 |
Why?
|
| Ecchymosis | 1 | 2021 | 12 | 0.730 |
Why?
|
| Orbital Cellulitis | 3 | 2012 | 14 | 0.730 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2021 | 3 | 0.730 |
Why?
|
| Acrospiroma | 1 | 2021 | 5 | 0.720 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2021 | 25 | 0.720 |
Why?
|
| Vitamin K | 1 | 2021 | 38 | 0.710 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2021 | 17 | 0.710 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2020 | 6 | 0.700 |
Why?
|
| Corneal Dystrophies, Hereditary | 1 | 2020 | 10 | 0.690 |
Why?
|
| Optic Nerve Injuries | 1 | 2020 | 11 | 0.690 |
Why?
|
| Postoperative Complications | 6 | 2019 | 3178 | 0.690 |
Why?
|
| Intense Pulsed Light Therapy | 1 | 2020 | 1 | 0.680 |
Why?
|
| Skin Aging | 2 | 2013 | 12 | 0.670 |
Why?
|
| Visual Fields | 2 | 2020 | 147 | 0.670 |
Why?
|
| Ependymoglial Cells | 1 | 2020 | 10 | 0.670 |
Why?
|
| Apraxias | 1 | 2020 | 15 | 0.660 |
Why?
|
| Cornea | 6 | 2020 | 594 | 0.660 |
Why?
|
| Basketball | 1 | 2019 | 2 | 0.660 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2020 | 71 | 0.660 |
Why?
|
| Acellular Dermis | 1 | 2019 | 7 | 0.660 |
Why?
|
| Polytetrafluoroethylene | 1 | 2020 | 76 | 0.650 |
Why?
|
| Plant Extracts | 1 | 2021 | 138 | 0.650 |
Why?
|
| Prostaglandins, Synthetic | 1 | 2019 | 3 | 0.650 |
Why?
|
| Skin Transplantation | 1 | 2019 | 59 | 0.640 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2019 | 14 | 0.620 |
Why?
|
| Keratitis | 2 | 2018 | 110 | 0.620 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2019 | 33 | 0.620 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2020 | 73 | 0.620 |
Why?
|
| Compartment Syndromes | 1 | 2019 | 31 | 0.610 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 86 | 0.610 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 453 | 0.610 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2018 | 9 | 0.610 |
Why?
|
| Encephalocele | 1 | 2019 | 48 | 0.600 |
Why?
|
| Systemic Vasculitis | 1 | 2018 | 2 | 0.600 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 907 | 0.600 |
Why?
|
| Immunosuppressive Agents | 3 | 2018 | 703 | 0.600 |
Why?
|
| Arteriovenous Fistula | 1 | 2019 | 56 | 0.590 |
Why?
|
| Aged | 23 | 2024 | 21775 | 0.580 |
Why?
|
| Polyethylene | 4 | 2008 | 15 | 0.580 |
Why?
|
| Lymph Nodes | 1 | 2020 | 399 | 0.580 |
Why?
|
| Conjunctivitis | 1 | 2018 | 22 | 0.570 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2018 | 92 | 0.570 |
Why?
|
| Pituitary Neoplasms | 1 | 2019 | 85 | 0.560 |
Why?
|
| Biological Products | 1 | 2020 | 138 | 0.560 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2017 | 25 | 0.560 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 566 | 0.560 |
Why?
|
| Abscess | 4 | 2008 | 140 | 0.560 |
Why?
|
| Meningioma | 1 | 2019 | 143 | 0.550 |
Why?
|
| Internship and Residency | 3 | 2023 | 1250 | 0.550 |
Why?
|
| Retrospective Studies | 22 | 2024 | 17540 | 0.550 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2021 | 342 | 0.540 |
Why?
|
| Adenoma | 1 | 2019 | 143 | 0.540 |
Why?
|
| Forecasting | 1 | 2019 | 377 | 0.540 |
Why?
|
| Meningeal Neoplasms | 1 | 2019 | 219 | 0.530 |
Why?
|
| Consensus | 1 | 2020 | 732 | 0.530 |
Why?
|
| Middle Aged | 27 | 2024 | 29399 | 0.510 |
Why?
|
| Face | 4 | 2021 | 190 | 0.510 |
Why?
|
| Edema | 1 | 2017 | 140 | 0.500 |
Why?
|
| Embolization, Therapeutic | 3 | 2019 | 225 | 0.490 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2015 | 19 | 0.490 |
Why?
|
| Nose Neoplasms | 1 | 2015 | 34 | 0.480 |
Why?
|
| Orbital Myositis | 2 | 2012 | 4 | 0.480 |
Why?
|
| Eye Pain | 2 | 2012 | 11 | 0.480 |
Why?
|
| Rhytidoplasty | 2 | 2007 | 8 | 0.470 |
Why?
|
| Nasal Cavity | 1 | 2015 | 52 | 0.470 |
Why?
|
| Laser Therapy | 2 | 2011 | 227 | 0.470 |
Why?
|
| Ectropion | 2 | 2007 | 5 | 0.470 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 296 | 0.460 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 691 | 0.460 |
Why?
|
| United States | 14 | 2025 | 11763 | 0.450 |
Why?
|
| Sensation | 2 | 2007 | 52 | 0.450 |
Why?
|
| Adult | 26 | 2024 | 31945 | 0.440 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 7217 | 0.430 |
Why?
|
| Glaucoma | 3 | 2019 | 89 | 0.430 |
Why?
|
| Diagnosis, Differential | 6 | 2023 | 1979 | 0.430 |
Why?
|
| Hyaluronic Acid | 2 | 2025 | 109 | 0.430 |
Why?
|
| Enophthalmos | 1 | 2013 | 9 | 0.420 |
Why?
|
| Sulfonamides | 1 | 2015 | 287 | 0.420 |
Why?
|
| Follow-Up Studies | 8 | 2024 | 5477 | 0.410 |
Why?
|
| Rejuvenation | 1 | 2013 | 12 | 0.400 |
Why?
|
| Graft Rejection | 1 | 2017 | 630 | 0.400 |
Why?
|
| Viscosupplements | 1 | 2013 | 7 | 0.400 |
Why?
|
| Esthetics | 1 | 2013 | 38 | 0.400 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2012 | 8 | 0.390 |
Why?
|
| Positron-Emission Tomography | 2 | 2023 | 311 | 0.390 |
Why?
|
| Silicon Dioxide | 1 | 2012 | 31 | 0.390 |
Why?
|
| Catheters | 1 | 2013 | 89 | 0.380 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 1853 | 0.380 |
Why?
|
| Fibroma | 1 | 2012 | 31 | 0.380 |
Why?
|
| Patient Preference | 1 | 2014 | 136 | 0.380 |
Why?
|
| Varicose Veins | 1 | 2012 | 31 | 0.380 |
Why?
|
| Nevus, Pigmented | 1 | 2011 | 33 | 0.370 |
Why?
|
| Catheterization | 1 | 2013 | 239 | 0.360 |
Why?
|
| Prostheses and Implants | 3 | 2021 | 152 | 0.360 |
Why?
|
| Vision Disorders | 2 | 2025 | 221 | 0.350 |
Why?
|
| Adenocarcinoma, Sebaceous | 2 | 2000 | 8 | 0.340 |
Why?
|
| Brain | 2 | 2019 | 3224 | 0.340 |
Why?
|
| Sebaceous Gland Neoplasms | 2 | 2000 | 15 | 0.340 |
Why?
|
| Eye Abnormalities | 2 | 2001 | 103 | 0.340 |
Why?
|
| Strabismus | 1 | 2011 | 55 | 0.330 |
Why?
|
| Craniocerebral Trauma | 1 | 2011 | 138 | 0.330 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2023 | 3857 | 0.320 |
Why?
|
| Treatment Outcome | 14 | 2020 | 13074 | 0.320 |
Why?
|
| Recurrence | 4 | 2024 | 1472 | 0.320 |
Why?
|
| Endoscopy | 1 | 2011 | 287 | 0.310 |
Why?
|
| Fever | 1 | 2012 | 312 | 0.310 |
Why?
|
| Amyloid | 2 | 2021 | 69 | 0.310 |
Why?
|
| Cellulitis | 2 | 2007 | 63 | 0.300 |
Why?
|
| Cyanoacrylates | 2 | 2005 | 12 | 0.290 |
Why?
|
| Tissue Adhesives | 2 | 2005 | 39 | 0.290 |
Why?
|
| Postoperative Period | 3 | 2020 | 343 | 0.290 |
Why?
|
| Paresis | 1 | 2008 | 33 | 0.280 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 2007 | 21 | 0.280 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 370 | 0.280 |
Why?
|
| Biopsy | 5 | 2024 | 1304 | 0.280 |
Why?
|
| Bupivacaine | 1 | 2008 | 29 | 0.280 |
Why?
|
| Cytomegalovirus Retinitis | 2 | 2018 | 14 | 0.280 |
Why?
|
| Epistaxis | 2 | 2004 | 12 | 0.280 |
Why?
|
| Glucocorticoids | 2 | 2012 | 403 | 0.270 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2007 | 41 | 0.270 |
Why?
|
| Anesthetics, Local | 1 | 2008 | 90 | 0.260 |
Why?
|
| Fatal Outcome | 2 | 2019 | 378 | 0.260 |
Why?
|
| Treatment Failure | 2 | 2019 | 367 | 0.260 |
Why?
|
| Contracture | 1 | 2006 | 26 | 0.260 |
Why?
|
| Eyebrows | 1 | 2006 | 13 | 0.250 |
Why?
|
| Injections | 3 | 2018 | 156 | 0.250 |
Why?
|
| Entropion | 1 | 2006 | 1 | 0.250 |
Why?
|
| Langer-Giedion Syndrome | 1 | 2006 | 3 | 0.250 |
Why?
|
| Eyeglasses | 1 | 2005 | 11 | 0.250 |
Why?
|
| Photophobia | 1 | 2005 | 9 | 0.250 |
Why?
|
| Infant | 12 | 2024 | 13240 | 0.250 |
Why?
|
| Periostitis | 1 | 2005 | 2 | 0.250 |
Why?
|
| Lymphoma, Follicular | 1 | 2005 | 30 | 0.240 |
Why?
|
| Eye Evisceration | 2 | 2004 | 3 | 0.240 |
Why?
|
| Giant Cell Arteritis | 1 | 2006 | 59 | 0.240 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2016 | 138 | 0.240 |
Why?
|
| Dermal Fillers | 1 | 2025 | 4 | 0.240 |
Why?
|
| Paranasal Sinus Diseases | 2 | 2021 | 15 | 0.240 |
Why?
|
| Dermatitis, Perioral | 1 | 2004 | 2 | 0.230 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2019 | 195 | 0.230 |
Why?
|
| Prospective Studies | 7 | 2022 | 6601 | 0.230 |
Why?
|
| Silicone Elastomers | 4 | 2024 | 22 | 0.220 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2024 | 64 | 0.210 |
Why?
|
| Lubricants | 1 | 2023 | 3 | 0.210 |
Why?
|
| Drainage | 3 | 2018 | 265 | 0.210 |
Why?
|
| Young Adult | 6 | 2023 | 9944 | 0.210 |
Why?
|
| Adolescent | 15 | 2024 | 20624 | 0.210 |
Why?
|
| Exophthalmos | 3 | 2018 | 35 | 0.210 |
Why?
|
| Suture Techniques | 1 | 2005 | 188 | 0.210 |
Why?
|
| Risk Factors | 6 | 2024 | 11182 | 0.210 |
Why?
|
| Hematoma | 1 | 2004 | 94 | 0.200 |
Why?
|
| Child | 15 | 2024 | 25890 | 0.200 |
Why?
|
| Child, Preschool | 11 | 2024 | 14884 | 0.200 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 177 | 0.200 |
Why?
|
| Operating Rooms | 1 | 2023 | 75 | 0.200 |
Why?
|
| Maxillary Fractures | 1 | 2022 | 11 | 0.200 |
Why?
|
| Maxillofacial Injuries | 1 | 2022 | 9 | 0.200 |
Why?
|
| Allografts | 2 | 2020 | 198 | 0.200 |
Why?
|
| Twins, Monozygotic | 1 | 2023 | 129 | 0.200 |
Why?
|
| Chronic Disease | 2 | 2023 | 1250 | 0.200 |
Why?
|
| Nose | 1 | 2023 | 105 | 0.190 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 239 | 0.190 |
Why?
|
| Eye Infections, Bacterial | 3 | 2024 | 86 | 0.190 |
Why?
|
| Blepharophimosis | 1 | 2001 | 26 | 0.180 |
Why?
|
| Tooth Abnormalities | 1 | 2001 | 10 | 0.180 |
Why?
|
| Intraocular Pressure | 3 | 2015 | 136 | 0.180 |
Why?
|
| Granuloma | 2 | 2016 | 68 | 0.180 |
Why?
|
| Cytokines | 1 | 2007 | 1401 | 0.180 |
Why?
|
| Ophthalmoscopy | 2 | 2018 | 35 | 0.180 |
Why?
|
| Wounds, Gunshot | 1 | 2022 | 147 | 0.180 |
Why?
|
| Osteochondrodysplasias | 1 | 2001 | 67 | 0.180 |
Why?
|
| Wound Healing | 1 | 2005 | 488 | 0.180 |
Why?
|
| Time Factors | 3 | 2020 | 6610 | 0.180 |
Why?
|
| Gigantism | 1 | 2000 | 14 | 0.180 |
Why?
|
| Prosthesis Failure | 1 | 2002 | 162 | 0.170 |
Why?
|
| Coloring Agents | 1 | 2001 | 78 | 0.170 |
Why?
|
| Multivariate Analysis | 1 | 2024 | 1492 | 0.170 |
Why?
|
| Indocyanine Green | 1 | 2001 | 62 | 0.170 |
Why?
|
| Stents | 2 | 2018 | 877 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 377 | 0.170 |
Why?
|
| Intubation | 2 | 2015 | 15 | 0.170 |
Why?
|
| Early Diagnosis | 2 | 2018 | 200 | 0.170 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3668 | 0.170 |
Why?
|
| Angiography | 1 | 2001 | 215 | 0.170 |
Why?
|
| Calcinosis | 1 | 2002 | 193 | 0.170 |
Why?
|
| Decompression, Surgical | 1 | 2020 | 92 | 0.170 |
Why?
|
| Eye Protective Devices | 1 | 2019 | 8 | 0.160 |
Why?
|
| Perceptual Disorders | 1 | 1999 | 4 | 0.160 |
Why?
|
| Optical Illusions | 1 | 1999 | 3 | 0.160 |
Why?
|
| Reflex, Vestibulo-Ocular | 1 | 1999 | 23 | 0.160 |
Why?
|
| Bioengineering | 1 | 2019 | 15 | 0.160 |
Why?
|
| Hemangioma, Capillary | 1 | 2020 | 17 | 0.160 |
Why?
|
| Administration, Ophthalmic | 1 | 2019 | 7 | 0.160 |
Why?
|
| Prednisolone | 1 | 1999 | 79 | 0.160 |
Why?
|
| Oxygen | 1 | 2023 | 582 | 0.160 |
Why?
|
| Dexamethasone | 1 | 2021 | 282 | 0.160 |
Why?
|
| Nystagmus, Pathologic | 1 | 1999 | 25 | 0.160 |
Why?
|
| Cleft Lip | 1 | 2001 | 134 | 0.160 |
Why?
|
| Cleft Palate | 1 | 2001 | 155 | 0.160 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 176 | 0.160 |
Why?
|
| Gentamicins | 1 | 1999 | 96 | 0.160 |
Why?
|
| Ophthalmic Nerve | 1 | 2019 | 6 | 0.160 |
Why?
|
| Cerebral Angiography | 1 | 2019 | 106 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 4 | 2024 | 2578 | 0.150 |
Why?
|
| Hemangioma | 1 | 2020 | 97 | 0.150 |
Why?
|
| Vestibular Diseases | 1 | 1999 | 68 | 0.150 |
Why?
|
| Brachytherapy | 1 | 2019 | 93 | 0.150 |
Why?
|
| Retinal Diseases | 1 | 2001 | 181 | 0.150 |
Why?
|
| Mycophenolic Acid | 1 | 2018 | 60 | 0.150 |
Why?
|
| Acute Disease | 2 | 2018 | 1192 | 0.150 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 198 | 0.140 |
Why?
|
| Pain | 1 | 2021 | 476 | 0.140 |
Why?
|
| Chemoprevention | 1 | 2018 | 58 | 0.140 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2019 | 73 | 0.140 |
Why?
|
| Neurotoxins | 1 | 2018 | 58 | 0.140 |
Why?
|
| History, 19th Century | 1 | 2018 | 120 | 0.140 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 56 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2021 | 514 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 1310 | 0.130 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 135 | 0.130 |
Why?
|
| Reoperation | 2 | 2015 | 856 | 0.130 |
Why?
|
| Remission Induction | 1 | 2017 | 310 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2018 | 277 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2018 | 396 | 0.120 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2015 | 6 | 0.120 |
Why?
|
| Choroid Diseases | 1 | 2016 | 23 | 0.120 |
Why?
|
| Training Support | 1 | 2015 | 19 | 0.120 |
Why?
|
| Injections, Intraocular | 2 | 2012 | 10 | 0.120 |
Why?
|
| Awareness | 1 | 1996 | 80 | 0.120 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2001 | 1000 | 0.120 |
Why?
|
| Meibomian Glands | 1 | 2015 | 44 | 0.120 |
Why?
|
| Education, Medical, Graduate | 2 | 2023 | 560 | 0.120 |
Why?
|
| Pandemics | 1 | 2023 | 1190 | 0.120 |
Why?
|
| Sirolimus | 1 | 2017 | 253 | 0.120 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 118 | 0.120 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 2015 | 60 | 0.120 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 972 | 0.120 |
Why?
|
| Eye | 2 | 2016 | 245 | 0.120 |
Why?
|
| HIV | 1 | 2016 | 195 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 1409 | 0.110 |
Why?
|
| Abnormalities, Multiple | 1 | 2000 | 979 | 0.110 |
Why?
|
| Ethmoid Sinus | 2 | 2004 | 9 | 0.110 |
Why?
|
| Incidence | 2 | 2019 | 3416 | 0.110 |
Why?
|
| Biocompatible Materials | 2 | 2008 | 129 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2016 | 243 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 1787 | 0.110 |
Why?
|
| Health Policy | 1 | 2015 | 233 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 507 | 0.100 |
Why?
|
| Necrosis | 1 | 2013 | 221 | 0.100 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 132 | 0.100 |
Why?
|
| Triamcinolone | 1 | 2012 | 15 | 0.100 |
Why?
|
| Diplopia | 1 | 2012 | 38 | 0.100 |
Why?
|
| Medicare | 1 | 2015 | 466 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 3114 | 0.090 |
Why?
|
| Herpesvirus 2, Human | 1 | 2011 | 14 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2013 | 311 | 0.090 |
Why?
|
| Eye Diseases | 1 | 2013 | 130 | 0.090 |
Why?
|
| Herpesvirus 1, Human | 1 | 2011 | 34 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 1 | 1992 | 284 | 0.090 |
Why?
|
| Eye Infections, Viral | 1 | 2011 | 28 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 2011 | 57 | 0.090 |
Why?
|
| Orbital Pseudotumor | 1 | 2010 | 10 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 649 | 0.090 |
Why?
|
| Prosthesis Design | 1 | 2013 | 661 | 0.080 |
Why?
|
| Disease Progression | 2 | 2018 | 2266 | 0.080 |
Why?
|
| Porosity | 2 | 2008 | 44 | 0.080 |
Why?
|
| Syndrome | 3 | 2004 | 1167 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2016 | 553 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1996 | 905 | 0.080 |
Why?
|
| Baseball | 1 | 2009 | 6 | 0.080 |
Why?
|
| Fixation, Ocular | 1 | 2009 | 18 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2006 | 772 | 0.080 |
Why?
|
| Wounds, Penetrating | 1 | 2009 | 142 | 0.070 |
Why?
|
| Athletic Injuries | 1 | 2009 | 64 | 0.070 |
Why?
|
| Thailand | 2 | 2018 | 44 | 0.070 |
Why?
|
| HIV Infections | 1 | 2000 | 2075 | 0.070 |
Why?
|
| Patient Selection | 1 | 2011 | 735 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2008 | 242 | 0.070 |
Why?
|
| Fluorophotometry | 2 | 2012 | 30 | 0.070 |
Why?
|
| Periosteum | 1 | 2007 | 33 | 0.070 |
Why?
|
| Prosthesis Implantation | 2 | 2015 | 152 | 0.070 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 107 | 0.070 |
Why?
|
| Facial Muscles | 1 | 2007 | 26 | 0.070 |
Why?
|
| Necrobiotic Disorders | 1 | 2006 | 2 | 0.060 |
Why?
|
| Xanthomatosis | 1 | 2006 | 8 | 0.060 |
Why?
|
| Scleritis | 1 | 2006 | 10 | 0.060 |
Why?
|
| Tissue Fixation | 1 | 2006 | 41 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 1218 | 0.060 |
Why?
|
| Light | 1 | 2005 | 183 | 0.060 |
Why?
|
| Silicones | 1 | 2024 | 33 | 0.060 |
Why?
|
| Data Collection | 1 | 2006 | 399 | 0.060 |
Why?
|
| Durapatite | 1 | 2004 | 15 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 136 | 0.060 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2004 | 39 | 0.060 |
Why?
|
| Maxillary Artery | 1 | 2004 | 3 | 0.060 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2004 | 32 | 0.050 |
Why?
|
| Ophthalmoplegia | 1 | 2004 | 58 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2004 | 121 | 0.050 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2024 | 17 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 572 | 0.050 |
Why?
|
| Aspergillosis | 1 | 2004 | 47 | 0.050 |
Why?
|
| Blindness | 1 | 2004 | 76 | 0.050 |
Why?
|
| Debridement | 1 | 2004 | 91 | 0.050 |
Why?
|
| Facial Nerve | 1 | 2003 | 26 | 0.050 |
Why?
|
| Anti-Dyskinesia Agents | 1 | 2003 | 39 | 0.050 |
Why?
|
| Intraoperative Complications | 1 | 2004 | 165 | 0.050 |
Why?
|
| Eye Movements | 2 | 2002 | 79 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2008 | 573 | 0.050 |
Why?
|
| Exotropia | 1 | 2002 | 18 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2007 | 8623 | 0.050 |
Why?
|
| Prosthesis-Related Infections | 1 | 2024 | 188 | 0.050 |
Why?
|
| Biomarkers | 2 | 2007 | 3434 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2024 | 275 | 0.050 |
Why?
|
| Asia | 1 | 2002 | 127 | 0.050 |
Why?
|
| Fluorescein | 1 | 2001 | 39 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2024 | 645 | 0.040 |
Why?
|
| Fundus Oculi | 1 | 2001 | 68 | 0.040 |
Why?
|
| Iris | 1 | 2000 | 50 | 0.040 |
Why?
|
| Orbit Evisceration | 1 | 2000 | 5 | 0.040 |
Why?
|
| Fluorescein Angiography | 1 | 2001 | 154 | 0.040 |
Why?
|
| Head Movements | 1 | 1999 | 27 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2000 | 38 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2023 | 314 | 0.040 |
Why?
|
| Propranolol | 1 | 2020 | 130 | 0.040 |
Why?
|
| Cataract | 1 | 2000 | 174 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 820 | 0.040 |
Why?
|
| Nerve Regeneration | 1 | 2019 | 85 | 0.040 |
Why?
|
| Tremor | 1 | 1999 | 135 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2000 | 675 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 252 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1317 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 367 | 0.030 |
Why?
|
| Hospitalization | 1 | 2005 | 1906 | 0.030 |
Why?
|
| Tuberculosis, Ocular | 1 | 2016 | 4 | 0.030 |
Why?
|
| Personnel Downsizing | 1 | 2015 | 1 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 239 | 0.030 |
Why?
|
| Minocycline | 1 | 2015 | 42 | 0.030 |
Why?
|
| Azithromycin | 1 | 2015 | 47 | 0.030 |
Why?
|
| Tonometry, Ocular | 1 | 2015 | 30 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2015 | 37 | 0.030 |
Why?
|
| Doxycycline | 1 | 2015 | 121 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2018 | 574 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2018 | 709 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 727 | 0.030 |
Why?
|
| Population Surveillance | 1 | 1996 | 419 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 194 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 1996 | 469 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 1992 | 50 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 1992 | 92 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 1992 | 258 | 0.020 |
Why?
|
| Epithelium | 1 | 1992 | 366 | 0.020 |
Why?
|
| Acyclovir | 1 | 2011 | 47 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1157 | 0.020 |
Why?
|
| Valine | 1 | 2011 | 116 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2010 | 105 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2011 | 221 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 2684 | 0.020 |
Why?
|
| Pregnancy | 1 | 2001 | 7570 | 0.020 |
Why?
|
| Ethmoid Sinusitis | 1 | 2008 | 3 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2008 | 118 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 3754 | 0.020 |
Why?
|
| Sinusitis | 1 | 2007 | 114 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1992 | 1072 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2011 | 824 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 3999 | 0.010 |
Why?
|
| Ligation | 1 | 2004 | 137 | 0.010 |
Why?
|
| Bacteria | 1 | 2007 | 537 | 0.010 |
Why?
|
| Arteries | 1 | 2004 | 231 | 0.010 |
Why?
|
| Tomography, Optical Coherence | 1 | 2006 | 569 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1356 | 0.010 |
Why?
|